Vidofludimus is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus also can be used for the research of fatty liver by targeting FXR[1][2][3].
Molekulargewicht:
355.36
Reinheit:
99.14
CAS Nummer:
[717824-30-1]
Formel:
C20H18FNO4
Target-Kategorie:
Dihydroorotate Dehydrogenase,FXR,Interleukin Related
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten